welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer jumps on 7-year-old data
Acer Therapeutics Inc. had a welcoming first week on the Nasdaq stock exchange, seeing shares sruge more 10% Monday after verifying positive clinical results published almost seven years ago from a study of celiprolol, the active ingredient in its lead drug candidate.
The study tested celiprolol against placebo in patients with vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening disorder that causes arteries and organs to easily rupture. After receiving treatment for about four years on average, 20% of the participants in the investigational arm experienced arterial events versus 50% of those in the control arm.
expertly curated content related to this topic
-
The EDSers United Foundation Research Library for EDSThe following information made available...
-
My Disability | Ehlers Danlos Syndomehttps://www.youtube.com/watch?v=q7rRrV5y...
-
The Driscoll Theory Newly Revised: The Cause of POTS in Ehlers-Danlos Syndrome and How to Reverse the ProcessThe Driscoll Theory was a complete parad...
-
Patient Education Program and Ehlers-Danlos Syndrome (PREDUSED)The Ehlers-Danlos Syndrome (SED) compris...
-
Ehlers-Danlos SyndromeWhen I first saw this girl, who is aged ...